Atopic Dermatitis | AbbVie | M16-045
Pharmaceutical Company/Sponsor:
AbbVie
Code:
M16-045
Title:
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis
Type:
Interventional
Phase:
3
Condition/Disease:
Atopic Dermatitis
Intervention(s)/Treatment(s):
Drug: Upadacitinib
Drug: Placebo for Upadacitinib
Status:
Recruiting
Link for Additional Information:
